Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? - Suppr

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?

Srinivas N R

Zydus Research Center, Ahmedabad, Gujarat, India.

Aliment Pharmacol Ther. 2016 Oct;44(7):771-2. doi: 10.1111/apt.13743.

Abstract

摘要

Aliment Pharmacol Ther. 2016 Oct;44(7):771-2. doi: 10.1111/apt.13743.

Aliment Pharmacol Ther. 2016 Oct;44(7):772-3. doi: 10.1111/apt.13768.

Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):885-91. doi: 10.1097/MEG.0b013e32836220ab.

Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80. doi: 10.1111/j.1365-2036.2007.03254.x.

J Crohns Colitis. 2014 May;8(5):375-83. doi: 10.1016/j.crohns.2013.09.017. Epub 2013 Oct 12.

Orv Hetil. 2009 Oct 4;150(40):1858-60. doi: 10.1556/OH.2009.28731.

Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. doi: 10.1111/apt.13880. Epub 2016 Dec 19.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):210. doi: 10.1016/j.cgh.2014.06.012. Epub 2014 Jun 19.

Aliment Pharmacol Ther. 2017 Mar;45(6):855-856. doi: 10.1111/apt.13929.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。